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Abstract. Hoogeveen EK, Kostense PJ, Jakobs C,
Rauwerda JA, Dekker JM, Nijpels G, Bouter LM, Heine
RJ, Stehouwer CDA (University Hospital Vrije Uni-
versiteit, Amsterdam). Hyperhomocysteinaemia is
not associated with isolated crural arterial occlusive
disease: the Hoorn Study. J Intern Med 2000; 247:
442±448.
Objectives. Hyperhomocysteinaemia is an indepen-
dent risk factor for peripheral arterial disease (PAD).
The localization of peripheral arterial disease is
clinically relevant, because proximal (aortoiliac and
femoropopliteal) disease is associated with a parti-
cularly poor overall prognosis, whereas isolated distal
(i.e. crural) disease is associated with a better overall
prognosis. The aim of the study was to investigate
whether the strength of the association between
hyperhomocysteinaemia and peripheral arterial dis-
ease differs according to the localization of the
anatomical obstruction.
Design. Fasting serum total homocysteine (tHcy)
was measured in an age-, sex- and glucose-tolerance
stratified random sample (n = 631) of a 50- to 75-
year-old general Caucasian population. History of a
peripheral arterial reconstruction was recorded.
Aortoiliac, femoropopliteal and crural arterial ob-
structions were registered by means of Doppler flow
velocity curves.
Results. The median serum tHcy level was
12.2 mmol L21 (interquartile range: 10.0±15.3) in
men and 10.7 mmol L21 (interquartile range: 9.0±
13.3) in women. The prevalences of aortoiliac,
femoropopliteal and crural obstructions were 2.1%,
2.7% and 11.9%, respectively. After adjustment for
age, sex, systolic blood pressure, current smoking,
serum cholesterol and diabetes mellitus, the odds
ratios (95% confidence interval) per 5 mmol L21 tHcy
increment were 1.41 (1.05±1.89) for aortoiliac, 1.03
(0.70±1.52) for femoropopliteal and 0.82 (0.59±
1.15) for crural obstructions. Finally, diabetes
mellitus, HbA1c and current smoking were signifi-
cantly associated with crural and femoropopliteal
disease, whereas systolic blood pressure was sig-
nificantly associated with aortoiliac obstructions.
Conclusions. The present study indicates that
hyperhomocysteinaemia is associated with aortoiliac
but not with isolated crural arterial occlusive disease.
Keywords: atherosclerosis, diabetes mellitus, homo-
cysteine, hypertension, peripheral arterial disease.
Introduction
Peripheral arterial disease (PAD) has two important
clinical consequences: it is associated with an
increased risk of overall mortality, presumably
because it is a marker of generalized atherosclerosis,
and it impairs local blood flow, which may result in
ischaemic symptoms, such as intermittent claudica-
tion and critical limb ischaemia [1±3]. Peripheral
arterial disease can occur from the aortoiliac to the
crural territories. The localization of peripheral
arterial disease is clinically relevant, because prox-
imal (aortoiliac and femoropopliteal) disease is often
accessible to local treatment, but is thought to be
associated with a particularly poor overall prog-
nosis, whereas isolated distal (i.e. crural) disease is
often difficult to treat locally, but is associated with a
better overall prognosis than proximal arterial
disease [4]. It is therefore of interest to investigate
whether risk factors for proximal versus distal
peripheral arterial disease are different. In this
regard, it is well-established that diabetes mellitus
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is more strongly associated with distal peripheral
arterial disease, whereas smoking, hypertension and
hypercholesterolaemia are more closely associated
with proximal peripheral arterial disease [5±8].
Hyperhomocysteinaemia is a novel risk factor for
cardiovascular disease, which is independent of
classic risk factors such as smoking, hypercholester-
olaemia, diabetes mellitus and hypertension [9±12].
Although the mechanisms by which homocysteine
promotes atherothrombosis are unknown, the epi-
demiologic evidence of the association of hyperho-
mocysteinaemia with atherothrombotic disease is
strong [9, 13]. A high serum total homocysteine
(tHcy) concentration can be lowered with folic acid
supplementation [14]. Studies which specifically
investigated the relationship between hyperhomo-
cysteinaemia and peripheral arterial disease are
relatively scarce [15±19]. It is not known whether
the strength of the association between hyperhomo-
cysteinaemia and peripheral arterial disease is
similar for proximal and distal disease.
In order to further explore this issue, we compared
the strength of the association between tHcy and
other risk factors on the one hand and the level of
peripheral arterial obstruction (i.e. aortoiliacal
versus femoropopliteal versus crural), on the other




The Hoorn Study is a cross-sectional survey of
glucose tolerance and other cardiovascular risk
factors in a 50- to 75-year-old general Caucasian
population conducted from 1989 to 1992. A
random sample of all men and women aged 50±
75 years was drawn from the municipal population
registry office of Hoorn (the Netherlands); 2484
subjects participated (response rate 71%). An
extensive peripheral arterial investigation (detailed
below) was performed in an age-, sex- and glucose
tolerance-stratified random subsample (n = 631;
response rate 89%) [20]. The Hoorn Study was
approved by the Ethical Review Committee of the
University Hospital Vrije Universiteit. Informed
consent was obtained from all participants.
The peripheral arterial history was obtained by
means of a self-administered questionnaire and, if
positive, accepted only when confirmed by written
information of the participant's general practitioner.
Flow velocity curves were recorded, by one of two
experienced vascular technicians, from the femoral,
popliteal, posterior tibial and dorsalis pedis arteries
by means of a 5 or 8 MHz bi-directional continuous
wave Doppler connected to a real-time frequency
analyser. Tri- or biphasic curves indicate a normal
arterial inflow to that level. Monophasic or absent
curves are considered abnormal, signifying the
presence of an obstruction of 50% or more, proximal
to the examination site [21±23]. An aortoiliac
obstruction was defined as an abnormal Doppler
flow velocity curve from the femoral, the popliteal
and the three crural arteries, or having received a
bifurcation prosthesis; a femoropopliteal obstruction
as a normal flow velocity curve from the femoral
artery in combination with abnormal curves from
the popliteal artery and the crural arteries, or
having received a femoropopliteal reconstruction;
and a crural obstruction as normal curves from the
femoral and the popliteal arteries in combination
with an abnormal curve from one or more of the
crural arteries. The absence of, or presence of a
monophasic Doppler flow velocity curve only from
the peroneal artery in combination with normal
curves from the other two crural arteries and an
ankle brachial pressure index (ABPI) .0.9 in the
same limb was considered a technical failure
(n = 18). The ABPI, an estimate of the overall
severity of occlusive disease, was obtained by means
of Doppler-assisted systolic blood pressure measure-
ments taken from the brachial and the three crural
arteries on both sides as previously described in
more detail [20].
Measurement of serum total homocysteine
Fasting blood samples were centrifuged within
1 hour following collection. Serum was stored at ±
20 8C for 4±6 years. There is good evidence that
serum tHcy levels in frozen samples are stable for
10 years or more [24]. Serum total (free plus protein
bound) homocysteine level was measured by using
tri-n-butylphosphine as the reducing agent and
ammonium 7-fluorobenzo-2-oxa-1,3-diazole-4-sul-
phonate as the thiol-specific fluorochromophore,
followed by high performance liquid chromatogra-
phy with fluorescence detection [25]. The intra- and
interassay coefficients were 2.1% and 5.1%.
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Other cardiovascular risk factors
We measured fasting serum total cholesterol, HDL
cholesterol and triglycerides by enzymatic techni-
ques (Boehringer-Mannheim, Mannheim, Ger-
many). The Friedewald formula was used to
calculate the low density lipoprotein (LDL) choles-
terol concentration, except in subjects with serum
triglyceride levels greater than 8.0 mmol L21
(n = 3) [26]. Blood pressure was measured on the
right arm of seated subjects, after at least 5 min of
rest, using a random zero sphygmomanometer
(Hawksley-Gelman Ltd, Lancing, Sussex, UK). The
average of duplicate measurements on two occa-
sions was used for analysis. Hypertension was
defined as a blood pressure $160 mmHg systolic
and/or $95 mmHg diastolic and/or the current use
of antihypertensive medication. Normal glucose
tolerance, impaired glucose tolerance and diabetes
mellitus were defined according to the WHO criteria
(1985) [27] applied to the mean of two oral glucose
tolerance tests, except in patients with drug-treated
diabetes mellitus, as previously described in detail
[20]. Glycated haemoglobin (HbA1c) was determined
by an ion-exchange high-performance liquid chro-
matography, using a Modular Diabetes Monitoring
System (Bio-Rad, Veenendaal, the Netherlands).
Immunospecific insulin was measured in serum by
a double-antibody radioimmunoassay (lot SP21,
Linco Research, St Louis, USA). The interassay
coefficient of variation was 6%. The lower limit of
sensitivity was 12 pmol L21. Subjects were classified
as either nonsmoker or current smoker. Body mass
index (BMI) was calculated as weight divided by
height squared (kg m22). Waist and hip circumfer-
ences were measured and the waist±hip ratio (WHR)
was calculated as described elsewhere [20]. Central
adiposity was defined as a WHR . 1.00 in men and
.0.90 in women. All laboratory and vascular
measurements were carried out by technicians
unaware of the subjects' history of peripheral
arterial disease and glucose tolerance status.
Statistical analysis
Variables are presented as mean 6 standard devia-
tion (SD), number (percentage of the total) or, in
case of skewed distribution, median and interquar-
tile range). The most proximal obstruction of either
limb was used for statistical analysis. We performed
logistic regression analyses to study the associations
of serum tHcy and of other cardiovascular risk
factors with each level of peripheral arterial disease.
As the dependent variable we took aortoiliac,
femoropopliteal or crural obstruction and contrasted
each group with subjects without any peripheral
arterial disease. We chose this procedure because, in
subjects with aortoiliac or femoropopliteal disease,
more distal (i.e. femoropopliteal or crural, respec-
tively) disease cannot be excluded. For tHcy, we
calculated odds ratios (ORs) and 95% confidence
intervals (CIs) per 5 mmol L21 (about 1 SD) incre-
ment of serum tHcy. We used multiple logistic
regression analysis, after adjustment for age and sex,
to investigate the associations between level of
peripheral arterial disease and systolic blood pres-
sure, serum total cholesterol, current smoking,
diabetes mellitus and tHcy. We also tested models
which included triglycerides, HDL and LDL choles-
terol, glucose, HbA1c, insulin, BMI and/or WHR. The
small number of cases with aortoiliac or femoropo-
pliteal obstruction did not allow for extensive
multivariate adjustment, nor for analyses of hyper-
tension as the dichotomous variable. We repeated all
analyses without taking peripheral arterial recon-
structions into account. All reported P-values are
two-tailed. All analyses were performed with SPSS
for Windows 7.5.2.
Results
Table 1 shows the characteristics of the study
population. Ten subjects had previously had a
peripheral arterial reconstruction: three of these
had had an aortoiliacal bifurcation prosthesis and
seven a femoropopliteal bypass. Two subjects had
previously undergone a limb amputation, so data
apply to only one leg. One of these subjects had a
traumatic limb amputation, which was not con-
sidered as peripheral arterial disease. Table 2 shows
the prevalences of peripheral arterial disease accord-
ing to localization of it. After exclusion of subjects
who had undergone reconstructive surgery, an
ABPI , 0.5 (a proxy measure of multilevel disease
[28]) was present in 50% (five out of 10) of the
subjects with an aortoiliac obstruction and 28.6%
(four out of 14) of the subjects with a femoropopli-
teal obstruction. The small number of subjects did
not allow further analysis of the determinants of
proximal peripheral arterial disease as defined here,
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i.e. without or with multilevel disease, versus the
determinants of isolated proximal peripheral arterial
disease, i.e. proximal peripheral arterial disease
without multilevel disease.
The median serum tHcy level was 12.2 mmol L21
(interquartile range: 10.0±15.3) in men and
10.7 mmol L21 (interquartile range: 9.0±13.3) in
women. We found a positive association between
the serum tHcy level and more proximally located
lower limb arterial obstruction (Table 2). The odd's
ratios did not change materially when subjects with
a history of vascular reconstruction were excluded
(data not shown).
After adjustment for age and sex, we found that
diabetes mellitus, HbA1c and current smoking were
significantly associated with crural and femoropo-
pliteal obstruction, whereas systolic blood pressure
was significantly associated with aortoiliac obstruc-
tion (Table 3). Additional adjustment for use of
antihypertensives (yes/no) did not materially
change the association between blood pressure and
aortoiliac obstruction (odd's ratio 1.26; 1.10±1.46;
95% CI). Total cholesterol was more strongly
associated with aortoiliac than distal peripheral
obstruction (Table 3), although the association with
aortoiliac obstruction was not statistically signifi-
cant (P = 0.3). After adjustment for HbA1c, the
strength of the association between diabetes and
aortoiliac disease was not attenuated, whereas that
with femoropopliteal obstruction was. Impaired
glucose tolerance was not significantly associated
with any obstruction (data not shown). We there-
fore pooled subjects with normal and impaired
glucose tolerance in all analyses. HDL cholesterol,
triglycerides, fasting insulin, BMI and WHR were
not significantly associated with a specific level of
peripheral arterial disease and adjusting for each of
theses variables did not materially affect the
association between diabetes and crural, femoropo-
pliteal or aortoiliac obstruction (data not shown).
We considered subjects with a monophasic
Doppler flow velocity curve from only the peroneal
artery and an ABPI . 0.9 in the same limb not to
have crural disease (n = 18; see methods). Categor-
ization of these subjects as having crural disease did
not materially affect the results (data not shown).
Finally, the number of premenopausal women
(n = 13; defined as those women who had menstr-
uated within the last year) was too small to allow for
a subanalysis of the association between tHcy and
localization of peripheral arterial disease before and
after menopause. Exclusion of premenopausal wo-
men did not materially affect the results (data not
shown).
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Table 1 Characteristics of the study population
n 631
Men (%) 48
Age (years) 64.3 (7.2)
Body mass index (kg m22) 27.3 (4.0)
Waist±hip ratio 0.92 (0.09)
Current smoker (%) 29
Systolic blood pressure (mmHg) 139 (19)
Diastolic blood pressure (mmHg) 83 (10)
Hypertension (%) 39.1
Impaired glucose tolerance (%) 26.9
Diabetes mellitus (%) 27.4
HbA1c (% of haemoglobin) 5.9 (1.3)
Fasting insulin (pmol L21) 84 (63±119)*
Total cholesterol (mmol L21) 6.6 (1.2)
HDL cholesterol (mmol L21) 1.3 (0.4)
LDL cholesterol (mmol L21) 4.5 (1.1)
Triglycerides (mmol L21) 1.6 (1.1±2.2)*
Total homocysteine (mmol L21) 11.4 (9.3±14.1)*
Data are presented as mean (SD). *Median (interquartile range).










Any 105 16.6 (13.7±19.5) 1.08 (0.92±1.27) 1.04 (0.87±1.24) 1.03 (0.85±1.23)
Aortoiliacb 13 2.1 (1.1±3.5) 1.37** (1.11±1.68) 1.36** (1.11±1.68) 1.41* (1.05±1.89)
Femoropoplitealc 17 2.7 (1.6±4.3) 1.11 (0.82±1.50) 1.06 (0.71±1.57) 1.03 (0.70±1.52)
Crural 75 11.9 (9.4±14.4) 0.87 (0.67±1.14) 0.81 (0.59±1.11) 0.82 (0.59±1.15)
aAdjusted for age, sex, diabetes mellitus (yes/no), systolic blood pressure, current smoking (yes/no) and serum cholesterol. bAortoiliac
obstruction (n = 10) and/or bifurcation prosthesis (n = 3). cFemoropopliteal obstruction (n = 14) and/or femoropopliteal reconstruction
(n = 7). *P < 0.05; **P < 0.01. OR: odds ratio, CI: confidence interval. Note: each level of peripheral arterial obstruction was contrasted
with subjects without any obstruction.
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Discussion
There are two main findings of this study. Firstly,
hyperhomocysteinaemia is more strongly associated
with proximal than with distal peripheral arterial
disease. Secondly, diabetes, level of glycaemia
(estimated from HbA1c) and current smoking were
associated with crural and femoropopliteal disease,
whereas systolic blood pressure was associated with
aortoiliac obstructions.
Others reported that hyperhomocysteinaemia is
associated with peripheral arterial disease [10, 15±
18]. The current study brings the association
between hyperhomocysteinaemia and localization
of peripheral arterial disease into focus. Although
there are no previous studies that have addressed
this issue, several observations from studies in which
serum total homocysteine (tHcy) was not measured
may support this finding. Firstly, premature periph-
eral atherosclerosis (i.e. disease affecting those under
50 years) is often located in the aortoiliac bed, i.e.
proximally [5], and is known to be associated with
hyperhomocysteinaemia [15, 16, 18]. Secondly,
aortoiliac obstruction without distal occlusions
occurs twice as often in (premature) postmenopau-
sal compared with premenopausal women [29, 30],
and postmenopausal women have higher serum
tHcy levels than premenopausal women [31].
Several pathophysiological mechanisms have been
proposed through which hyperhomocysteinaemia
may induce atherosclerosis. Hyperhomocysteinae-
mia may induce dysfunction of the vascular
endothelium [32±34], a critical initiating event in
the development of atherosclerosis. In addition,
hyperhomocysteinaemia may stimulate proliferation
of vascular smooth muscle cells and elastinolytic
processes in the arterial wall [34±37]. Atherosclero-
sis occurs at definite sites of predilection within the
vascular tree, such as bifurcations, angulations or
fixed points. The abdominal aorta is at high risk of
atherosclerosis due to the thickness of the avascular
zone of the arterial wall, which increases the risk of
ischaemia. However, it is not known how hyperho-
mocysteinaemia affects the mechanisms leading to
aortoiliac as opposed to more distal atherosclerosis.
This study confirms that diabetes is associated
with distal peripheral arterial disease [4, 8]. After
adjustment for HbA1c the association between
diabetes and crural or femoropopliteal obstruction
disappeared. Adjustment for other factors of the
insulin resistance syndrome did not affect the
associations. This result may indicate that hypergly-
caemia itself is more important with regard to the
development of crural obstruction than other factors
of the insulin resistance syndrome [38]. Finally, the
present study also confirms that systolic blood
pressure is more closely associated with proximal
arterial disease, and, in addition, suggests that
systolic blood pressure is probably not a risk factor
for crural disease.
We have to consider several limitations of the
present study. Firstly, we relied on a noninvasive
technique to assess peripheral arterial disease which
detects the most proximal obstruction rather than
the degree or extent of the obstruction. Although
angiography is not suitable for a population-based
study, duplex scanning would have provided more
precise information on the extent and severity of
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Diabetes mellitus (yes/no) 2.77 (0.90±8.51) 4.33** (1.58±11.87) 1.98** (1.19±3.28) 1.11 (0.54±2.25)
HbA1c (per percentage) 1.22 (0.80±1.84) 1.65*** (1.26±2.16) 1.42*** (1.21±1.67) 1.42*** (1.14±1.76)
Current smoking (yes/no) 1.34 (0.39±4.53) 4.19*** (1.53±11.51) 2.49*** (1.47±4.21) 2.65*** (1.54±4.57)
Total cholesterol (per mmol L21) 1.28 (0.83±1.99) 1.15 (0.77±1.71) 1.00 (0.82±1.23) 0.95 (0.77±1.17)
Systolic blood pressure (per 5 mmHg) 1.29*** (1.13±1.46) 1.09 (0.97±1.24) 0.94 (0.88±1.01) 0.93 (0.87±1.00)
aAdjusted for age, sex and diabetes mellitus (yes/no), current smoking (yes/no), and HbA1c if this was not the variable under consideration.
bAortoiliac obstruction and/or bifurcation prosthesis. cFemoropopliteal obstruction and/or femoropopliteal reconstruction. *P < 0.05;
**P < 0.01; ***P < 0.001. OR: odds ratio, CI: confidence interval. Note: after adjustment for age, sex and HbA1c, the ORs (95% CIs) for the
association between diabetes mellitus and aortoiliac and femoropopliteal obstruction were 2.91 (0.77±11.00) and 2.06 (0.55±7.63).
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obstruction. As a consequence, we could not
distinguish whether hyperhomocysteinaemia is
especially associated with obstructions confined to
the aortoiliac region or with multilevel disease [15].
The small number of subjects with an ABPI , 0.5, a
proxy of multilevel disease [28], did not allow
further analysis of this issue. Secondly, since the
present study is cross-sectional, we cannot rule out
that hyperhomocysteinaemia is a consequence of
the disease rather than a cause. However, there is
increasing evidence that the relation between tHcy
and cardiovascular disease is causal [9, 11, 12,
32±37]. Finally, the small number of subjects with a
proximal arterial obstruction warrants careful inter-
pretation of the results of the present study.
Proximal aortoiliac disease is associated with a
particularly poor overall prognosis. Therefore, the
results of the present study may have clinical
relevance because hyperhomocysteinaemia can ef-
fectively be lowered through an increased intake of B
vitamins, particularly folate [14].
In conclusion, hyperhomocysteinaemia and sys-
tolic blood pressure are more strongly associated
with proximal than with distal peripheral arterial
disease, whereas diabetes and level of glycaemia are
associated with distal and possibly with proximal
peripheral arterial disease.
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